Keliximab

Names

[ Name ]:
Keliximab

Biological Activity

[Description]:

Keliximab (SB-210396) is a chimeric human/macaque IgG1 anti-CD4 monoclonal antibody with a Ki value of 1.0 nM for soluble CD4. Keliximab blocks T cell proliferation and inhibits IL-2 production. Keliximab can be used for cancer research[1][2].

[Related Catalog]:

Research Areas >> Cancer

Signaling Pathways >> Immunology/Inflammation >> Interleukin Related

[In Vitro]

Keliximab 与可溶性 CD4 结合的 Kd 值为 1.0 nM[2]。 Keliximab (0.01-10 μg/mL；30 分钟) 剂量依赖性地结合 CD4+ 胸腺瘤细胞系 SupT1，ED50 为 0.2 μg/mL[1]。 Keliximab (0-1000ng/mL) 在原发性人浆母细胞淋巴瘤 (PBLs) 中阻断 T 细胞增殖和 IL-2 产生，IC50 为 10-30 ng/mL[1]。 Keliximab (1-1000 ng/mL；5 分钟) 剂量依赖性地介导细胞粘附，ED50 为 20 ng/mL[1]。

[In Vivo]

Keliximab (5-125 mg/kg；静脉注射，1 次) 减少 CD4+ T 细胞[1]。 Animal Model: Transgenic mice bearing human CD4 molecules on their T cells[1] Dosage: 5-125 mg/kg Administration: Intravenous injection, 5-125 mg/kg, once Result: Dose-dependently down-modulated CD4 and rapidly declined the number of circulating CD4+ T cells compared with clenoliximab.

[References]

[1]. Sharma A, et al. Comparative pharmacodynamics of keliximab and clenoliximab in transgenic mice bearing human CD4. J Pharmacol Exp Ther. 2000 Apr;293(1):33-41.

[2]. Anderson D, et al. A primatized MAb to human CD4 causes receptor modulation, without marked reduction in CD4+ T cells in chimpanzees: in vitro and in vivo characterization of a MAb (IDEC-CE9.1) to human CD4. Clin Immunol Immunopathol. 1997 Jul;84(1):73-84.

Chemical & Physical Properties

No Any Chemical & Physical Properties

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.